FindTrial
Sign In

Expanded Access for Vepugratinib (LY3866288) in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors

Expanded Access for Vepugratinib in Participants With Fibroblast Growth Factor Receptor 3 (FGFR3) Altered Solid Tumors

Status
AVAILABLE
Phases
Unknown
Study type
Expanded Access
Source
ClinicalTrials.gov
Registry ID
NCT07675057
Enrollment
Unknown
Registered
2026-06-30
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Carcinoma, Transitional Cell, Neoplasm Metastasis, Urinary Bladder Neoplasms

Keywords

Metastatic Urothelial Carcinoma

Brief summary

The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

Interventions

DRUGVepugratinib

Administered orally

Sponsors

Eli Lilly and Company
Lead SponsorINDUSTRY

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum

Inclusion criteria

* Have metastatic urothelial carcinoma (UC) or other solid tumor with a qualifying fibroblast growth factor receptor 3 (FGFR3) genetic alteration. * Have exhausted other approved treatments, including erdafitinib for UC. * Are not eligible for an ongoing vepugratinib clinical trial

Exclusion criteria

* Currently enrolled in an ongoing clinical study of vepugratinib * Have a known severe (greater than or equal to (≥) Grade 3) hypersensitivity to any component or excipient of vepugratinib. * Current evidence of corneal keratopathy or retinal disorder confirmed by ocular examination. Exception: Individuals with asymptomatic ophthalmic conditions assessed by the investigator to pose minimal risk. * Significant cardiovascular disease: * Are pregnant, breastfeeding, or intent to become pregnant during the study or within 6 months of the last dose of study intervention.

Contacts

CONTACTThe Lilly Answers Center
1-800-LillyRx (1-800-545-5979)
STUDY_DIRECTORContact Lilly at 1-800-LillyRx (1-800-545-5979)

Eli Lilly and Company

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jul 1, 2026